Affimed Balans Gezondheid

Financiële gezondheid criteriumcontroles 3/6

Affimed heeft een totaal eigen vermogen van €17.2M en een totale schuld van €8.1M, wat de schuld-eigenvermogensverhouding op 46.9% brengt. De totale activa en totale passiva bedragen respectievelijk €40.0M en €22.8M.

Belangrijke informatie

46.9%

Verhouding schuld/eigen vermogen

€8.06m

Schuld

Rente dekkingsratio	n/a
Contant	€24.10m
Aandelen	€17.20m
Totaal verplichtingen	€22.76m
Totaal activa	€39.96m

Recente financiële gezondheidsupdates

Recent updates

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( €32.4M ) A28A } overtreffen de korte termijn passiva ( €16.8M ).

Langlopende schulden: De kortetermijnactiva A28A ( €32.4M ) overtreffen de langetermijnschulden ( €6.0M ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: A28A heeft meer geld in kas dan de totale schuld.

Schuld verminderen: De schuld/eigen vermogen-ratio van A28A is de afgelopen 5 jaar gestegen van 14.7% naar 46.9%.

Balans

Analyse van de cashflow

Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.

Stabiele cash runway: A28A heeft minder dan een jaar aan cash runway op basis van de huidige vrije kasstroom.

Voorspelling contante baan: A28A heeft minder dan een jaar aan kasmiddelen als de vrije kasstroom blijft dalen met historische percentages van 38.1 % per jaar.

Affimed Balans Gezondheid

Financiële gezondheid criteriumcontroles 3/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Affimed Announces Listing Transfer to Nasdaq Capital Markets

Recent updates

Affimed N.V. to Report Q3, 2024 Results on Nov 14, 2024

Affimed N.V. Announces Acceptance of Three Abstracts At the 2024 Ash Annual Meeting Including an Oral Presentation Underscoring Advancing Clinical Pipeline in Leukemia and Lymphoma

Affimed N.V. Announces Chief Executive Officer Changes

Affimed N.V. to Report Q2, 2024 Results on Sep 05, 2024

Affimed N.V. to Report Q1, 2024 Results on Jun 12, 2024

Affimed N.V., Annual General Meeting, Jun 26, 2024

Affimed Announces Positive Early Efficacy and Progression Free Survival Results of AFM24-102 Study in EGFR Wild-Type Non-Small Cell Lung Cancer at the Annual Meeting of the American Society of Clinical Oncology 2024

Affimed N.V. to Report Fiscal Year 2023 Results on Mar 28, 2024

Affimed N.V. Provides Clinical Response Update on AFM24-102 Trial in EGFR-Wildtype Non-Small Cell Lung Cancer

Affimed N.V. Announces CEO Changes

Affimed Announces Updated Phase 1/2 Data from Acimtamig in Combination with Allogeneic Nk in Hodgkin Lymphoma Patients Who Failed Prior Chemotherapy and Are Double-Refractory to Brentuximab Vedotin (Bv) and Checkpoint Inhibitors (Cpis)

Affimed N.V. Announces Executive Changes

Affimed N.V. to Report Q3, 2023 Results on Nov 14, 2023

Affimed N.V. Presents Preclinical Data Showing That Addition of an Innate Cell Engager to Nk and Car-Nk Cells

Affimed N.V. Announces Oral Presentation of Phase 1/2 Data from AFM13 in Combination with Allogeneic NK Cells at the 2023 ASH Annual Meeting

Affimed Announces Listing Transfer to Nasdaq Capital Markets

Affimed Receives FDA Fast Track Designation for AFM13 in Combination with AlloNK(R) for the Treatment of Patients with Relapsed or Refractory Hodgkin Lymphoma

Affimed N.V. Announces Publication in the Journal mAbs on Leveraging FcRn-pH-HPLC as a Method to Select Bispecific Antibodies with Optimal Developability

Second quarter 2023 earnings released: €0.20 loss per share (vs €0.13 loss in 2Q 2022)

Affimed N.V. to Report Q2, 2023 Results on Aug 10, 2023

New minor risk - Market cap size

Affimed N.V.(NasdaqGM:AFMD) dropped from Russell 2000 Dynamic Index

Affimed Announces Addition of Constanze Ulmer-Eilfort to Its Supervisory Board

Affimed Announces IND Clearance for a Phase 2 Clinical Trial Investigating AFM13 and AB-101 Combination Therapy

First quarter 2023 earnings released: €0.21 loss per share (vs €0.14 loss in 1Q 2022)

Affimed N.V., Annual General Meeting, Jun 21, 2023

Affimed N.V. to Report Q1, 2023 Results on May 23, 2023

Affimed N.V. Announces Abstracts at Annual Meeting of European Hematology Association

Full year 2022 earnings released: €0.60 loss per share (vs €0.48 loss in FY 2021)

Affimed N.V. Provides Regulatory Update for AFM13

Affimed N.V. Announces Approval of Clinical Trial Application in France for a Phase 1 Study of AFM28 in Relapsed/Refractory Acute Myeloid Leukemia

Affimed N.V. Provides Updated Clinical Data from Phase 1/2 Study of AFM13 Precomplexed with Cord Blood-Derived NK Cells

Now 23% undervalued after recent price drop

Third quarter 2022 earnings released: €0.11 loss per share (vs €0.14 loss in 3Q 2021)

Affimed N.V. to Report Q3, 2022 Results on Nov 15, 2022

Affimed N.V. Announces Presentation of Phase 1/2 Data from Afm13 in Combination with Allogeneic NK Cells and Preclinical Afm28 Data At Ash 2022 Annual Meeting

Now 22% undervalued after recent price drop

Now 21% undervalued after recent price drop

Second quarter 2022 earnings released: €0.13 loss per share (vs €0.16 loss in 2Q 2021)

Affimed N.V. to Report Q2, 2022 Results on Aug 11, 2022

Affimed N.V. Establishes Scientific Advisory Board

Affimed Presents Preclinical Data of Novel Innate Cell Engager AFM28 at the Annual Meeting of the European Hematology Association (EHA)

First quarter 2022 earnings released: €0.14 loss per share (vs €0.012 profit in 1Q 2021)

Affimed N.V. Announces Highlights Trial Designs of Three AFM24 Ongoing Clinical Studies At the Annual Meeting of the American Society of Clinical Oncology

Affimed N.V. to Report Q1, 2022 Results on Jun 01, 2022

Affimed N.V. Presents Data on Innate Cell Engagers Afm24 and Afm28 at 19th Meeting of the Society for Natural Immunity

Affimed N.V. Announces Data from the Dose Escalation Phase of the Phase 1/2A Study with the company’s Innate Cell Engager

Affimed Presents Updated Clinical Data from Phase 1/2 Study of AFM13 Precomplexed with Cord Blood-Derived NK Cells at AACR Annual Meeting

Affimed N.V. Presents Findings from the Dose-Escalation Phase of the First-In-Human Study of AFM24 in Patients with EGFR-Positive Solid Tumors

Full year 2021 earnings released: €0.48 loss per share (vs €0.50 loss in FY 2020)

Affimed N.V. Announces Publication of Preclinical Data Demonstrating Cytotoxic Potency and Efficacy of NK Cells Precomplexed with Innate Cell Engagers After Freezing & Thawing

Affimed N.V. Announces Completion of Enrollment in Redirect, the Registration-Directed Study of Afm13 in PTCL

Affimed N.V. to Discuss Treatment of Cd30-Positive Lymphoma Patients with Cord Blood-Derived Natural Killer Cells Pre-Complexed with Innate Cell Engager AFM13

Affimed N.V. Initiates Patient Recruitment for A Phase 1/2A Trial of Innate Cell Engager Afm24 in Combination with Roche’S Anti-Pd-L1 Checkpoint Inhibitor Atezolizumab

Affimed Announces Interim Clinical Results from the Investigator-Initiated Phase 1-2 Study At the University of Texas MD Anderson Cancer Center

Third quarter 2021 earnings released: €0.14 loss per share (vs €0.069 loss in 3Q 2020)

Second quarter 2021 earnings released: €0.16 loss per share (vs €0.15 loss in 2Q 2020)

First quarter 2021 earnings released: EPS €0.012 (vs €0.11 loss in 1Q 2020)

Affimed N.V. Announces Publication of Preclinical Data in Clinical Cancer Research Supporting Therapeutic Potential of Afm13 in Combination with Natural Killer Cells

Full year 2020 earnings released: €0.50 loss per share (vs €0.50 loss in FY 2019)

Affimed N.V. Announces Continuation of REDIRECT, a Registration-Directed Study of AFM13 in PTCL, After Positive Preplanned Interim Futility Analysis

New 90-day low: €4.00

Affimed Announces Collaboration with Roche to Study AFM24 in Combination with PD-L1 Checkpoint Inhibitor in EGFR Expressing Solid Tumors

Affimed N.V. has completed a Follow-on Equity Offering in the amount of $100.000002 million.

Affimed Announces Pipeline and Business Update

New 90-day high: €5.67

Affimed N.V. Announces Publication of Final Study Results of Its Innate Cell Engager Candidate AFM13 in Combination with MSD’s Anti-PD-1 Therapy KEYTRUDA® (Pembrolizumab) in Blood

New 90-day high: €3.65

Revenue beats expectations

Third quarter 2020 earnings released: €0.069 loss per share

Affimed N.V. Announces Preclinical Data Generated Through Collaboration with the University of Texas MD Anderson Cancer Center and Washington University School of Medicine

Affimed N.V. and Roivant Sciences Enter Licensing and Strategic Collaboration Agreement

Artiva Biotherapeutics, Inc., and Affimed N.V. Announces Platform-To-Platform R&D Collaboration for Targeted Off-The-Shelf NK Cell Therapies

Affimed N.V. to Report Q3, 2020 Results on Nov 10, 2020